News
32m
FDA Approves EGRIFTA WR (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, representing +17% growth year over yearFDA Approves Prior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback